Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors
June 11 2019 - 7:00AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel cancer immunotherapies based
on tumor-infiltrating lymphocyte (TIL) technology, today announced
the appointment of Athena Countouriotis, M.D., to the company’s
Board of Directors, effective June 10, 2019. Dr. Countouriotis is
the President and Chief Executive Officer of Turning Point
Therapeutics and specialized in hematology and oncology in her
professional career.
“Dr. Countouriotis has a long record of successful leadership in
oncology drug development, and particular expertise in bringing
novel therapies through clinical development,” commented Maria
Fardis, Ph.D., President and Chief Executive Officer of Iovance
Biotherapeutics. “We are delighted to expand our Board with new
members with deep drug development experience.”
“I am excited to join the board at such an important time for
the company following the strong data shown at ASCO with LN-145 in
cervical cancer and with lifileucel in advanced melanoma,” said Dr.
Countouriotis. “Both therapies have such great potential to benefit
patients and I look forward to working with the company and the
board to make these therapies available to patients.”
Dr. Countouriotis previously served as Chief Medical Officer for
multiple public biotechnology companies, including Adverum
Biotechnologies, Halozyme Therapeutics and Ambit Biosciences.
Earlier in her career, Dr. Countouriotis led development of
products for Pfizer and Bristol-Myers Squibb, including Sutent,
Mylotarg, Bosulif and Sprycel. She currently serves on the board of
directors at Turning Point Therapeutics and Trovagene. Dr.
Countouriotis holds an undergraduate degree from the University of
California, Los Angeles and an M.D. from the Tufts University
School of Medicine. She received training at the University of
California, Los Angeles and at the Fred Hutchinson Cancer Research
Center in the Pediatric Hematology-Oncology Program.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to commercialize autologous cell
therapy products that amplify the body’s own immune response to
eradicate solid tumors or attack blood cancers. The company is
currently conducting the pivotal study innovaTIL-01 in patients
with metastatic melanoma. In addition, the company’s tumor
infiltrating lymphocyte (TIL) therapies are being investigated for
the treatment of patients with locally advanced, recurrent or
metastatic cancers including cervical, head and neck, and non-small
cell lung cancer. For more information, please visit
www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are
“forward-looking statements” of Iovance Biotherapeutics, Inc.
(hereinafter referred to as the “Company,” “we,” “us,” or “our”).
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. The forward-looking
statements include, but are not limited to, risks and uncertainties
relating to the success, timing, projected enrollment,
manufacturing and production capabilities, and cost of our ongoing
clinical trials and anticipated clinical trials for our current
product candidates (including both Company-sponsored and
collaborator-sponsored trials in both the U.S. and Europe), such as
statements regarding the timing of initiation and completion of
these trials; the timing of and our ability to obtain and maintain
FDA or other regulatory authority approval of, or other action with
respect to, our product candidates, including those product
candidates that have been granted breakthrough therapy designation
(“BTD”) or regenerative medicine advanced therapy designation
(“RMAT”) by the FDA; the strength of the Company’s product
pipeline; the successful implementation of the Company’s research
and development programs and collaborations; the Company’s ability
to obtain tax incentives and credits; the success of the Company’s
manufacturing, license or development agreements; the acceptance by
the market of the Company’s product candidates, if approved; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in the
Company’s business, including, without limitation; the preliminary
clinical results, including efficacy and safety results, from
ongoing Phase 2 studies may not be reflected in the final analyses
of these trials, including new cohorts within these trials, and may
not be supportive of product approval; the FDA or other regulatory
authorities may potentially delay the timing of their approval of,
or other action with respect to, the Company’s product candidates;
the Company’s ability to address FDA or other regulatory authority
requirements relating to its clinical programs and registrational
plans, such requirements including, but not limited to, clinical
and safety requirements as well as manufacturing and control
requirements; risks related to the Company’s ability to maintain
and benefit from accelerated FDA review designations, including BTD
and RMAT, which may not ultimately result in a faster development
process or review of the Company’s product candidates (and which
may later be rescinded by the FDA if such product candidates no
longer meet the conditions for qualification for the program), and
does not in any way assure approval of such product candidates by
the FDA or the ability of the Company to obtain FDA approval in
time to benefit from commercial opportunities; and the ability of
the Company to manufacture its therapies using third party
manufacturers. A further list and description of the
Company’s risks, uncertainties and other factors can be found in
the Company’s most recent Annual Report on Form 10-K and the
Company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or www.iovance.com. The forward-looking statements are
made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
Investor Relations Contacts: Annie
ChangSolebury Trout646-378-2972achang@troutgroup.com
Chad RubinSolebury Trout646-378-2947crubin@troutgroup.com
Media Relations Contact: Rich AllanSolebury
Trout646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2024 to May 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From May 2023 to May 2024